Alembic Pharmaceuticals’ JV gets tentative approval for Efinaconazole Topical Solution

08 Apr 2021

Alembic Pharmaceuticals’ joint venture (JV) -- Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. 

Efinaconazole Topical Solution, 10% has an estimated market size of $ 233 million for twelve months ending December 2020. Aleor has settled the case with Bausch Health and. will launch its generic as per the terms of settlement. Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Related Alembic Pharmaceuticals Ltd. Links:

Alembic Pharma Share Price

1000.60 28.60 (2.94%) Apr 16, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 646.05
Dr. Reddys Lab 4893.00
Lupin 1055.85
Piramal Enterprises 1719.50
Cadila Healthcare 527.00
View more..
Sensex vs Alembic Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback